Novo Nordisk A/S, of Bagsvaerd, Denmark, said the Quebec government approved the inclusion of Victoza (liraglutide), the first once-daily human glucagon-like peptide-1 analogue, to the Lists of Medications. Quebec becomes the first province to provide public access to the drug.